Protection of non-human primates against rabies with an adenovirus recombinant vaccine  by Xiang, Z.Q. et al.
Protection of non-human primates against rabies with an adenovirus
recombinant vaccine
Z.Q. Xiang a, L. Greenberg b, H.C. Ertl a,n, C.E. Rupprecht c,d
a The Wistar Institute of Anatomy & Biology, Philadelphia, PA, United States
b Centers for Disease Control & Prevention, Atlanta, GA, United States
c The Global Alliance for Rabies Control, Manhattan, KS, United States
d Ross University School of Veterinary Medicine, Basseterre, St. Kitts, West Indies
a r t i c l e i n f o
Article history:
Received 24 September 2013
Returned to author for revisions
17 October 2013
Accepted 20 December 2013
Available online 9 January 2014
Keywords:
Adenoviral vaccine
NHP
Rabies virus
VNA
a b s t r a c t
Rabies remains a major neglected global zoonosis. New vaccine strategies are needed for human rabies
prophylaxis. A single intramuscular immunization with a moderate dose of an experimental chimpanzee
adenovirus (Ad) vector serotype SAd-V24, also termed AdC68, expressing the rabies virus glycoprotein,
resulted in sustained titers of rabies virus neutralizing antibodies and protection against a lethal rabies
virus challenge infection in a non-human primate model. Taken together, these data demonstrate the
safety, immunogenicity, and efﬁcacy of the recombinant Ad-rabies vector for further consideration in
human clinical trials.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Rabies virus causes an acute progressive viral encephalitis, with
the highest case fatality of any infectious disease (Jackson, 2009).
Although rabies is one of the oldest recognized zoonoses, it
remains a neglected disease, resulting in tens of thousands of
human fatalities, and tens of millions of annual exposures (http://
www.who.int/mediacentre/factsheets/fs099/en/). Rabies virus is
most commonly transmitted by dogs in the developing world.
Children are at high risk of exposure, and nearly half of rabies-
related fatalities affect children below the age of 16. In parts of
Africa, Asia, and Latin America, outdated nerve tissue-based
vaccines are still used, some unchanged little from the time of
Pasteur (Wu et al., 2011). Modern human vaccines, while highly
efﬁcacious, are expensive, and require multiple doses for the
elicitation of protective immunity (Rupprecht et al., 2009; health.
costhelper.com/rabies-vaccine.html). In general, rabies vaccines
are given after a bite, as post-exposure prophylaxis (PEP). In cases
of severe exposure, active immunization has to be combined with
passive immunization with a rabies virus immune globulin pre-
paration of human (HRIG) or equine origin (ERIG), both of which
are costly and habitually in short supply (Jentes et al., 2013; http://
www.who.int/ith/vaccines/rabies/en/). Development of novel
inexpensive, safe and effective rabies biologics for human popula-
tions at risk would be a major advantage for rabies prevention in
the developing world. It is well established that protection against
rabies virus is mediated by neutralizing antibodies and titers at or
above 0.5 international units (IU) in general protect. Induction of
rabies virus neutralizing antibodies (VNA) have been shown to be
critical in protection of experimental animals exposed to rabies
virus, as well as humans bitten by rabid animals (Plotkin, 2010;
WHO Position Paper, 2007). Previous studies showed that inclu-
sion of a rabies vaccine into childhood immunizations resulted in
the development of memory B cells that rapidly mounted potent
rabies VNA recall responses after booster immunization
(Malerczyk et al., 2007; Suwansrinon et al., 2006). Nevertheless,
one study conducted in Thailand concluded that inclusion of rabies
vaccines into vaccination programs for children would not be cost
effective when compared to standard PEP (Chulasugandha et al.,
2006). A less expensive vaccine able to induce sustained rabies
VNA titers and durable memory B cell responses in a shortened
schedule may render preventative childhood vaccination more
cost-effective and thereby reduce the impact of rabies in devel-
oping countries, as well as of those deemed at risk of rabies virus
exposure in developed countries, such as veterinarians, diagnostic
workers, animal handlers, wildlife researchers, cavers, certain
travelers, selected members of the military, etc. (Manning et al.,
2008; http://www.who.int/ith/vaccines/rabies/en/).
The objective of this research was to test the comparative
safety, immunogenicity, and efﬁcacy of an adenovirus (Ad) vector
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expressing the rabies virus glycoprotein in a non-human primate
model. Most of these studies were conducted with chimpanzee-
derived Ad vectors. Humans only rarely demonstrate neutralizing
antibodies to such viruses (Chen et al., 2010; Xiang et al., 2006),
which may impair vaccine efﬁcacy. Vectors expressed the full-
length viral glycoprotein of the Evelyn Rokitnicki Abelseth (ERA)
strain of rabies virus. Immunization of nonhuman primates with
the Ad vectors induced high and sustained VNA titers to rabies
virus, conﬁrming previous studies performed in mice (Chen et al.,
2010; Xiang et al., 2002), which showed that Ad vectors, although
most commonly used for induction of cellular immune responses,
also elicited potent and durable transgene product-speciﬁc
humoral responses.
Results
Immunogenicity of Ad vectors used in a high dose prime-boost
regimen
A pilot experiment was conducted in two Chinese rhesus
macaques to test if Ad vectors expressing the rabies virus glyco-
protein induced rabies VNAs and if such responses could be
enhanced by booster immunizations. To this end, two monkeys
that had no detectable antibody titers to rabies virus or the Ad
vectors were immunized on day 0 with 1012 vp of the AdC7rab.gp
vector given intramuscularly (i.m.). Eight months later, they were
boosted with the same dose of the AdC6rab.gp vector given i.m.
Five months later, they were boosted i.m. with 1012 vp of the
AdHu5rab.gp vector. Blood was collected at several time points
after vaccination. Rabies VNA titers were determined from heat-
inactivated plasma. Plasma from naïve monkeys, and monkeys
immunized with vectors expressing an unrelated transgene were
included, but none of the latter developed detectable rabies VNAs
(o0.2 IU, data not shown). The experimental animals developed
VNA titers of approximately 10 IU after the ﬁrst immunization
(Fig. 1). Although values ﬂuctuated, titers were sustained for at
least 8 months. After the boost with AdC6rab.gp, rabies VNA titers
virus increased in both animals 10 fold. In one animal, rabies
VNA titers then contracted to levels obtained after priming, while
the other animal showed more sustained increases after the ﬁrst
boost. A second boost with an AdHu5rab.gp vector again increased
rabies VNA titers by more than 10 fold. Overall, these preliminary
results showed that Ad vector immunization induced a potent
and sustained rabies VNA response. In addition, vectors induced
memory B cells that readily differentiate into antibody-secreting
cells upon booster immunizations.
Vaccine efﬁcacy in a dose escalation study
The vector dose used in the above pilot study exceeded the
dose that would be expected to cause signiﬁcant toxicity in
humans. Although the AdC vectors we tested have not yet under-
gone testing in humans, other E1-deleted Ad vectors of human or
simian serotypes typically cause dose-limiting adverse events at
1011 vp (Harro et al., 2009). Therefore, we next tested the
AdC68rab.gp vector in a dose escalation experiment at 109 to
1011 vp in small groups of two cynomologous monkeys per group.
An AdC vector control was used at 1011 vp. A commercially
available human diploid cell rabies vaccine (HDCV), used intra-
muscularly at the recommended dose for pre-exposure vaccina-
tion, was included. The AdC vector vaccine was only given once,
and the HDCV was given three times on days 41, 27 and 20
in relation to the AdC vaccine. Animals were challenged at 18
weeks after the last vaccine dose with 106.4 (MICLD)50/ml as
calculated via the Spearman–Kaerber method, of a virulent street
strain of canine rabies virus. The two animals that received the
control vector developed signs of rabies. All other vaccinated
animals had detectable rabies VNA by day 7 post-immunization,
and remained disease-free (Fig. 2A).
Effect of pre-existing immunity to a human serotype Ad vector on the
efﬁcacy of AdC68rab.gp
Humans are exposed to Ad viruses and in response develop
neutralizing antibodies, which are serotype-speciﬁc, as well as
binding antibodies and T cells, which cross-react between different
human and simian serotypes (Hutnick et al., 2010; Xiang et al.,
2002). Numerous studies have shown that pre-existing neutraliz-
ing antibodies to Ad vectors impact their immunogenicity (McCoy
et al., 2007; McElrath et al., 2008; Roberts et al., 2006). Neutraliz-
ing antibodies to AdC68 virus are only found rarely in humans
(Xiang et al., 2002). Nevertheless, pre-existing binding antibodies
or T cells may also affect vector-induced immune responses.
Therefore, in the next experiment, we assessed the effect of pre-
exposure to AdHu5 virus on the efﬁcacy of the AdC68rab.gp
vaccine. To this end, groups of four animals were either pre-
exposed with 1012 vp of an AdHu5 vector expressing a reporter
protein, or they were left untreated. Four weeks later, the pre-
treated as well as the untreated animals were vaccinated with 1010
vp of AdC68rab.gp. A third positive control group of two animals
received HDCV, given three times on days 41, 27 and 20 in
relation to the AdC vaccination (given on day 0). Four control
animals received PBS. All vaccinated animals developed detectable
rabies VNA after immunization. Although due to the small num-
bers of animals there were no signiﬁcant differences between
the vaccine groups, there was a clear trend towards more rapid
responses in the HDCV vaccine group and slower responses in the
AdC68rab.gp group, which were even further delayed if animals
had been pre-exposed to the AdHu5 vector (Fig. 2D). Animals were
challenged with 105.2 MICLD50/ml of street rabies virus of
canine origin 18 weeks after AdC vaccination. As shown in
Fig. 2B, all of the AdC68rab.gp and HDCV vaccinated animals
survived the challenge, while two of four control animals devel-
oped signs of rabies, indicating that pre-existing immunity to
human serotype Ad vectors did not reduce the efﬁcacy of the
AdC68rab.gp vector. This is in agreement with previous studies
conducted by ourselves and others in laboratory rodents and
nonhuman primates, which showed that pre-existing immunity
Fig. 1. Induction of rabies VNA upon sequential immunizations with Ad
vectors. Two rhesus macaques, shown individually in circles or cross-ﬁlled squares,
were primed with AdC7rab.gp, and then boosted with AdC6rab.gp, with AdHu5rab.
gp administered at the time points indicated by the arrows. The rabies VNA titers
were measured from sera at various time points. Titers are shown as international
units (IU) according to a reference serum tested in parallel. Control animals
immunized with the same vectors, but expressing an antigen of HIV-1, were tested
as well, and their sera showed titers consistently below 0.05 IU (not shown).
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Fig. 2. Vaccine efﬁcacy in pre-exposure and post-exposure regimens. (A) Dose escalation: Cynomologous monkeys were vaccinated once with various doses (109–1011 vp)
of the AdC68rab.gp vector, a control AdC68 vector given at 1011 vp, or three doses of commercial human rabies vaccine, HDCV. Additional control animals received PBS only.
Animals were challenged with canine rabies virus at 18 weeks after AdC68 vaccination. Due to the small number of animals differences between the vaccine groups and
control animal were not signiﬁcant (p¼0.082 by Mantel Cox test). Combining all AdC68rab.gp-vaccinated animals resulted in a signiﬁcant difference to controls (p¼0.0082).
(B) Effect of pre-existing HAd-V5 neutralizing antibodies: Groups of monkeys were injected with 1012 vp of an AdHu5 vector expressing a reporter protein, or they were left
untreated. Four weeks later, pre-treated, as well as untreated animals, were vaccinated with 1010 vp of AdC68rab.gp. A positive control group received commercial human
rabies vaccine, HDCV given 3 times, and a negative control group received PBS. Animals were challenged with canine rabies virus 18 weeks after AdC vaccination and survival
was recorded. There was no signiﬁcant difference between vaccinated animals that had or had not been pre-exposed. (C) Post-exposure prophylaxis: Nonhuman primates
were infected with canine rabies virus. Six hours later, one group was vaccinated with 1010 vp of AdC68rab.gp and received commercial HRIG inﬁltrated at the rabies virus
inoculation site. An additional group was vaccinated with AdC68rab.gp, but without HRIG. A positive control group was treated with the traditional vaccine regimen, i.e.,
HRIG combined with 4 doses of commercial PCEC human rabies vaccine, the latter given on days 1, 8, 15 and 29 relative to challenge. Additional control groups only received
HRIG, a control AdC68 vector or PBS. Survival was recorded. There was no signiﬁcant difference between controls (PBS and Ad control combined) and animals that only
received AdC68rab.gp or AdC68rab.gp with RIG. Graphs (A)–(C) show percent of animals that survived without developing signs of rabies. Numbers of animals per group are
shown within each graph above the bars. (D) shows VNA titers of the animals that are also shown in Fig. B. Data are shown as median titers at different time points7 IQR.
Differences between VNA titers of the different cohorts were analyzed by 2-way Anova with Dunnett correction.
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to AdHu5 virus does not reduce the overall immunogenicity or
efﬁcacy of vaccines based on alternative Ad serotypes (McCoy
et al., 2007; Roberts et al., 2006; Xiang et al., 2002).
Efﬁcacy in post-exposure prophylaxis
In general, prevention of rabies occurs after exposure has
occurred. Prophylaxis after severe exposures, which should com-
mence as soon as possible, consists of careful wound cleaning,
active immunization given repeatedly over a course of 2–48
weeks, and a RIG preparation injected once into the site of
exposure (Manning et al., 2008; http://www.cdc.gov/rabies/medi
cal_care/). To assess if AdC68rab.gp would induce protective
immunity in a post-exposure model, a total of 18 nonhuman
primates were infected with 106.1 MICLD50/ml of a virulent
street rabies virus of canine origin. Six hours later, ﬁve animals
were vaccinated with 1010 vp of AdC68rab.gp. In addition, these
animals received commercial HRIG injected close to the rabies
virus challenge site, at a dose of 20 IU/kg. An additional ﬁve
animals were vaccinated with AdC68rab.gp, without HRIG. Two
animals were administered a traditional PEP regimen, i.e., HRIG
combined with four doses of a commercial puriﬁed chick embryo
cell (PCEC) human rabies vaccine, the latter given on days 1, 8, 15
and 29 relative to challenge. Two animals received HRIG only, two
animals received a control AdC68 vector, and two animals were
treated with PBS only. Thereafter, both animals given PBS only, and
one of two animals administered the AdC68 vector, displayed
clinical signs of rabies, were sedated, euthanized, and diagnosed
rabid. The combination of PCEC vaccine and HRIG provided
complete protection, as did HRIG inﬁltration, without addition of
vaccine. The AdC68rab.gp given with, or without HRIG, only
provided partial protection in four or two of ﬁve animals, respec-
tively. All surviving animals developed rabies VNA40.5 IU/ml
within 7 days of PEP initiation, and all had titers 42.8 IU/ml by
conclusion of the study at 4 months. These data, while based on
small groups of animals, suggest that AdC68rab.gp, although
highly efﬁcacious in a preventative setting, may not reliably
protect if given after exposure to rabies virus (Fig. 2C).
Longevity of AdC68rab.gp induced immune responses
Lastly, a longer term pre-exposure vaccination experiment was
conducted based upon the above preliminary results. On day 0, six
animals were vaccinated IM with 1 ml containing 109 vps of the
AdC68rab.gp vector. All vaccinated animals developed rabies VNA
within 30 days of immunization (Fig. 3A). Titers were remarkably
stable for at least 18 months. By 21 months, after vaccination, four
animals still had titers above 10 IU, and the other two animals had
titers of 1 IU. The AdC68rab.gp-immunized animals, together with a
group of ﬁve control animals, were challenged with 106.3 MICLD50/
ml of a virulent street rabies virus of canine origin, at 22 months after
vaccination. All control animals displayed signs of rabies, but all
vaccinated animals survived. No rabies virus antigens were detected
in the brains of the vaccinated animals at the conclusion of the study,
in contrast to control animals (Fig. 3B). Vaccinated animals demon-
strated a very robust anamnestic response within 7 days post-
challenge that at its peak showed on average 240-fold increases in
VNA titers compared to those measured pre-challenge. Although
rabies VNA responses contracted rapidly after challenge, they
remained elevated (8 fold) for the duration of the study (Fig. 3C).
Discussion
Globally, more than three quarters of the human population are
assumed to be at risk for rabies virus exposure (World Health
Organization, 2013). The ﬁve billion people living in Asia and
Africa are at high risk of exposure to rabid dogs, which accounts
for the majority of all human rabies-related fatalities (Knobel et al.,
2005). More than 15 million humans receive PEP each year, with
an estimated prevention of more than 300,000 deaths (World
Health Organization, 2013). In South East Asia, approximately
20 million people are bitten each year by dogs. Of those bitten,
more than 1.5 million receive PEP. Signiﬁcantly, PEP is given to
40% of children by the time they reach 16 years of age in Asia
and Africa (Meslin and Briggs, 2013). Based upon such alarming
statistics, rabies vaccine may be considered preventatively as part
of childhood immunization programs in countries with a high
incidence of rabies, given as a pre-exposure series (Ravish et al.,
2013). In case of subsequent exposure, follow-up with wound
cleaning and a booster immunization would be recommended
(World Health Organization, 2013). Immunological memory
provided by modern rabies vaccines is long lasting, on the
order of decades or more (Malerczyk et al., 2007; Suwansrinon
et al., 2006). Recall responses develop rapidly, so that RIG is
unnecessary.
Fig. 3. Vaccine immunogenicity and efﬁcacy in a long-term study. (A) VNA titers after immunization: Groups of 6 animals were vaccinated with 109 vp of AdC68rab.gp.
The rabies VNA titers were tested periodically from sera for a period of 21 months. The graph shows rabies VNA titers of individual animals. Differences between pre- and
post-vaccination samples assigning a titer of 0.06 IU, the limit of detection, to pre-vaccination samples showed signiﬁcant differences for post-vaccination samples collected
from months 2 to month 17 by the multiple t-test with Sidak Holms correction (mo 2 p¼0.0001, all other time points po0.0001). (B) Vaccine efﬁcacy: The vaccinated
animals shown in (A) were challenged with canine rabies virus at 22 months after immunization. An additional 5 unvaccinated animals were challenged as well. Survival was
recorded. Difference in survival was signiﬁcant by the Mantel–Cox test (p¼0.0005). (C) VNA titers after challenge: Sera from the vaccinated animals in (A) were tested the
day of challenge and then at the indicated time points after challenge for VNA titers to rabies virus. The graph shows rabies VNA titers of individual animals. The following
animals showed a signiﬁcant increase in titers after challenge, as tested for by two-way ANOVA with Sidak correction for multiple comparisons: A38428 (p¼0.032), A28100
(p¼0.0011), A28112 (p¼0.0012), A28111 (p¼0.0012), A28114 (po0.0001).
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As an example, a cost analysis was conducted for different
regimens on preventative vaccination vs. traditional PEP in Thai
children (Chulasugandha et al., 2006). Using the least expensive
vaccine regimens (intradermal vaccinationþERIG) it was estimated
that the cost for preventative vaccination followed by booster
immunizations would equal the cost of PEP with a dog bite
prevalence of 7%. Although the actual dog bite rate is not known
for Thailand, about 30% of children have been bitten by a dog by age
15, suggesting an annual incidence rate of 2.3 bites per 100,000.
The authors concluded that preventative childhood vaccination was
not cost-effective for Thai children (Chulasugandha et al., 2006). One
may assume that this type of cost analyses based on available
vaccines would be similar for other countries with a high incidence
of rabies.
By comparison, the AdC68rab.gp described in this manuscript
appears more immunogenic compared to licensed rabies vaccines by
reliably inducing high titers of VNA after a single immunization
without the addition of adjuvant. The vaccine also induces sustained
responses, which as shown here in nonhuman primates, remain at
adequate levels for over a year. Equally important, AdC68rab.gp
induces memory B cells, which upon rabies virus challenge mount
a rapid and potent recall response within a few days. This was
achieved with a very modest dose of 109 vp of vector, which is well
below the dose that is typically used for Ad vectors undergoing
clinical testing as vaccines for other infectious diseases, such as
human immunodeﬁciency virus-1 (HIV-1). A single dose regimen,
compared to a three-dose regimen, which is administered over a 3–4
week period, would be more convenient, should produce better
patient compliance, and by inference, most likely would also be more
cost-effective, especially if combined with other childhood vaccines.
Oral immunization may be advantageous, not only for free-ranging
animals but also for mass vaccination of children. We had shown
previously that mice immunized orally with AdC68rab.gp mounted
rabies virus-speciﬁc VNA and were protected against challenge (Zhou
and Ertl, 2006). Nevertheless, oral AdC68rab.gp immunization of non-
human primates failed to elicit adequate levels of rabies VNA (data
not shown), suggesting that, as shown by others (Mercier et al., 2007),
Ad vectors may need to be encapsidated to retain immunogenicity
upon targeting to the gastrointestinal tract of larger mammals.
Currently, Ad vectors are being explored as vaccine vectors for
other infectious diseases to which protection is linked to induction of
cellular responses, such as those caused by HIV-1 (Baden et al., 2012;
McElrath et al., 2008), hepatitis C virus (Barnes et al., 2012),
Plasmodium falciparum (Sheehy et al., 2012) or Mycobacterium tuber-
culosis (Hoft et al., 2012). A surrogate of adequate immunization
against rabies virus has been well deﬁned (Johnson et al., 2010).
Rabies VNAs at titers at or above 0.5 IU are deemed adequate as
evidence of a proper immunological response to prevent a productive
infection. Presumably, CD4þ T cells are needed to promote B cell
responses, but otherwise cell-mediated immunity does not contribute
prominently to the prevention of virus acquisition. Results shown
here demonstrate that Ad vectors induce very potent and sustained
antibody responses and are thus suited as vaccine carriers for
pathogens that are best prevented by humoral responses. These data
conﬁrm previous studies in laboratory rodents, where we compared
the AdHu5rab.gp vector to a DNA vaccine and a vaccinia-rabies
glycoprotein (V-RG) recombinant vaccine, both expressing the same
transgene product (Xiang et al., 1999, 1996). The VRG vaccine is
licensed for wildlife immunization, and as such has shown efﬁcacy in
a number of species such as raccoons, coyotes, and foxes (Brochier
et al., 1996; Weyer et al., 2009). By comparison, Ad-based vectors have
showed superior induction of rabies VNAs, as compared to the other
two vaccine platforms.
When used during PEP, the AdC68rab.gp vaccine did not induce
reliable protection. All non-lyssavirus recombinant vaccines,
including Ad vectors, V-RG, etc., ﬁrst have to synthesize the
transgene product before an immune response is elicited. In case
of PEP, rapid induction of an immune response is essential and the
delayed induction of responses may be detrimental. In our mind,
such recombinant vaccines, including AdC68rb.gp, therefore may
not be ideally suitable in exploration for PEP applications.
Taken together, these data demonstrate the safety, immuno-
genicity, and efﬁcacy of the AdC68rab.gp vaccine in a non-human
primate animal model. Such encouraging results should be sup-
portive towards the near-term consideration of human clinical
trials, particularly considering the low, single-dose delivery, with-
out the need for adjuvants. Together with improved local public
education, enhanced de-centralized laboratory-based surveillance,
mass canine rabies vaccination, and improved human prophylaxis,
such modern biologics will have a substantive role to play in global
rabies prevention and control strategies (Lembo, 2012).
Materials and methods
Viral vector
Brieﬂy, all Ad vectors were generated from recombinant viral
molecular clones, as described (Zhou et al., 2010). A number of
different Ad vectors derived from human and simian serotypes
were tested, speciﬁcally vectors based on human serotype 5 (HAd-
V5 vectors, referred to as AdHu5), and simian serotypes SAd-V23
(vectors called AdC6), SAd-V24 (vectors called AdC7) and SAd-V25
(vectors called AdC68). Of note, SAd-V24 and SAd-V25 are closely
related, and induce cross-neutralizing antibodies, while neutraliz-
ing antibodies to SAd-V23 fail to neutralize SAd-V24 or SAd-V25.
The viruses were deleted in the E1 region, and hence impaired in
their ability to replicate. An expression cassette containing
the rabies virus glycoprotein gene, under the control of a CMV
promoter, was placed into the E1 domain. Upon rescue and
expansion on HEK 293 cells, vectors were puriﬁed by CsCl gradient
centrifugations. Vectors were titrated for content of virus particles
[vps] by spectrophotometry at 260 nm using the formula:
OD260dilution1.11012. Content of infectious virus particles
was measured by nested RT-PCR with transgene or Ad (hexon)-
speciﬁc primers on RNA isolated from HEK 293 cells infected for
5–7 days with serial dilutions of the viral vector. Batches were
tested for endotoxin using the Limulus Amebocyte Lysate (LAL)
gel-clot method and a commercial kit. Genetic integrity and
identity were assessed by isolation of viral DNA. The recombinant
DNA, in parallel with the original molecular clones and shuttle
plasmids used for generating molecular clones, were digested with
a set of restriction enzymes and analyzed by gel electrophoresis.
Expression of the transgene product was conﬁrmed by immuno-
precipitation of lysates from transfected HeLa cells, and primary
vaccine immunogenicity was demonstrated in mice, as described
(Xiang et al., 2002). The Ad vectors expressing green ﬂuorescent
protein were used to measured antibodies to Ad vectors. These
vectors have been described previously (Xiang et al., 2002).
Nonhuman primates
Female or male cynomologous monkeys (Macaca fasicularis) or
Chinese rhesus macaques (Macaca mulatta) were used in the
studies. The M. facicularis were 1–2 years of age with weights
ranging from 1 to 6 kg. They were housed in the animal facility of
the Centers for Disease Control and Prevention (CDC), Atlanta, GA.
The M. mulatta were 2–3 years of age, housed in the Nonhuman
Primate Facility of the Division of Medical Genetics of the
University of Pennsylvania, Philadelphia, PA. The animals were
housed in pairs, until the time of rabies virus infection. Prior to
handling, animals were sedated with ketamine hydrochloride
Z.Q. Xiang et al. / Virology 450-451 (2014) 243–249 247
(10 mg/kg) or Telazol (3–5 mg/kg) intramuscularly (i.m.). All vac-
cines were given i.m. Blood samples were collected via venipunc-
ture from a peripheral vein and placed in serum separator tubes.
Typically, bleeding occurred once a week to once a month, with
6–7 ml collected per kg per month. Upon challenge with rabies
virus, animals were observed multiple times per day. Any altera-
tions in body mass, food consumption, or water intake were
monitored closely. Upon the demonstration of clinical signs
compatible with rabies (e.g., paresis, cranial nerve deﬁcits, etc.),
animals were sedated, and euthanized by intravenous barbiturate
overdose. Research was approved by the Institutional Animal Care
and Use Committees.
Virus neutralization assays
Serum was separated from clotted blot after low speed cen-
trifugation. Rabies virus neutralizing antibodies (VNAs) were
assayed using the rapid ﬂuorescent focus inhibition test (RFFIT),
with CVS-11 virus propagated upon MNA cells, as described (Louie
et al., 1975). As no ‘protective’ titers have been deﬁned, compara-
tive levels of rabies VNAs were deﬁned arbitrarily via the RFFIT,
using the World Health Organization recommendations of evi-
dence, with a level of 0.5 IU/ml considered as a minimum
adequate level of acceptable comparable induction, as compatible
with standard human clinical trial criteria (World Health
Organization, 2013). Neutralizing antibodies to Ad viruses were
measured as described (Xiang et al., 2006). Animals with circulat-
ing neutralizing antibody titers Z1:20 to the vaccine vectors were
not enrolled into the study.
Rabies virus challenge
Challenge viruses consisted of street rabies viruses of canine
origin, chosen based upon global public health relevance from the
New and Old Worlds, and preliminary non-human primate sus-
ceptibility data, prepared as previously described (Franka et al.,
2009; Rupprecht et al., 2005). Challenge virus stocks were main-
tained at 80 C, and were diluted using sterile PBS/2% heat-
inactivated equine serum or FBS. Typical rabies virus challenge
concentrations ranged from 105.2 to 106.4 mouse intracerebral
lethal dose (MICLD)50/ml. Sedated animals were inoculated in the
masseter muscles with 0.5 ml of canine rabies virus, with an
approximate lethal dose, estimated based upon prior titrations in
naïve animals from other studies. Brain tissue was removed from
euthanized animals. Rabies virus antigens were detected using the
direct ﬂuorescent antibody test, as described (Reid et al., 1983).
Statistical analyses
Comparisons between two sets of samples were conducted by
use of the Student0s t-test, and comparisons between multiple
samples were conducted by use of a 2-way ANOVA. The Sidak-
Holms correction was used to adjust for multiple comparisons.
Differences in survival were determined by Mantel–Cox tests.
Statistical analyses were conducted with GraphPad Prism,
version 6.0b.
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